This study showed that pembrolizumab alone improved OS compared with standard chemotherapy (14.9 months vs 10.7 months, HR 0.61, P = .001) in patients with ≥20 CPS (combined positive score; PD‐L1 expression in tumor and/or surrounding immune cells, divided by tumor cells).23 Despite these developments, there will always be patients who are not suitable for immunotherapy because of auto‐immune diseases or a PDL‐1 negative cancer and who are too vulnerable for treatment with platinum‐based chemotherapy. This evidence concerns the gene CD274 and immune system disorder.